MindMaze Therapeutics Holding (XSWX:MMTX) Asset Impairment Charge: CHF0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.18
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Asset Impairment Charge?

MindMaze Therapeutics Holding XSWX:MMTX +3.33% 4 Asset Impairment Charge is CHF0.00 Mil as of Jun. 2026. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's Asset Impairment Charge for the six months ended in Jun. 2026 was CHF0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was CHF0.00 Mil.

MindMaze Therapeutics Holding Asset Impairment Charge Related Terms

MindMaze Therapeutics Holding Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Asset Impairment Charge Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Asset Impairment Charge
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Jun25 Dec25 Jun26
Asset Impairment Charge 0.00 0.00 0.00 0.00
XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

What does a Asset Impairment Charge of CHF0.00 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Asset Impairment Charge of CHF0.00 Mil as of Jun. 2026.
Is MindMaze Therapeutics Holding's Asset Impairment Charge too high?
MindMaze Therapeutics Holding's current Asset Impairment Charge is CHF0.00 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Asset Impairment Charge compare to VRTX and REGN?
MindMaze Therapeutics Holding's Asset Impairment Charge of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. MindMaze Therapeutics Holding's current Asset Impairment Charge is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Asset Impairment Charge of CHF0.00 Mil. The current Asset Impairment Charge is CHF0.00 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Asset Impairment Charge is CHF0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.18
Price